{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:09:59Z","timestamp":1762762199785,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Pharmacology and Medical Formulation of Zaporizhzhia State Medical and Pharmaceutical University, &quot;The role of thioldisulfide system in the realization of mechanisms of neurodestruction\/neuroprotection and the development of ways of pharmaco","award":["No. 0123U101110"],"award-info":[{"award-number":["No. 0123U101110"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The intranasal route of drug administration is characterized by high bioavailability and is considered promising for rapid delivery of drugs with systemic action to the central nervous system (CNS), bypassing the blood-brain barrier. This is particularly important for the use of neuroprotective drugs in the treatment of brain tissue damage in infants caused by the effects of intrauterine hypoxia. The creation of new dosage forms for neonatology using mathematical technologies and special software in pharmaceutical development allows for the creation of cerebroprotective drugs with controlled pharmaco-technological properties, thus reducing time and resources for necessary research. We developed a new nasal gel formulation with Angiolin using a Box-Behnken experiment design for the therapy of prenatal CNS damage. It was found that the consistency characteristics of the nasal gel were significantly influenced by the gelling agent and mucoadhesive component\u2014sodium salt of carboxymethylcellulose. We optimized the composition of nasal gel formulation with Angiolin using the formed models and relationships between the factors. The optimized nasal gel composition demonstrated satisfactory thixotropic properties. The 1% gel for neuroprotection with Angiolin, developed for intranasal administration, meets all safety requirements for this group of drug forms, showing low toxicity and no local irritant or allergic effects.<\/jats:p>","DOI":"10.3390\/ph17080990","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T09:22:42Z","timestamp":1721985762000},"page":"990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and Optimization of Nasal Composition of a Neuroprotective Agent for Use in Neonatology after Prenatal Hypoxia"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1273-5314","authenticated-orcid":false,"given":"Igor","family":"Belenichev","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Medical Formulation with Course of Normal Physiology, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1287-674X","authenticated-orcid":false,"given":"Olena","family":"Aliyeva","sequence":"additional","affiliation":[{"name":"Department of Histology, Cytology and Embryology, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-7331","authenticated-orcid":false,"given":"Bogdan","family":"Burlaka","sequence":"additional","affiliation":[{"name":"Department of Medicines Technology, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Burlaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Diagnostics, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0029","authenticated-orcid":false,"given":"Oleh","family":"Kuchkovskyi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Medical Formulation with Course of Normal Physiology, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2210-8896","authenticated-orcid":false,"given":"Dmytro","family":"Savchenko","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Industrial Drug Technology, Bogomolets National Medical University, 01601 Kyiv, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-3791","authenticated-orcid":false,"given":"Valentyn","family":"Oksenych","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-4436","authenticated-orcid":false,"given":"Oleksandr","family":"Kamyshnyi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil State Medical University, 46001 Ternopil, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2741\/s252","article-title":"Intranasal treatment of neurodegenerative diseases and stroke","volume":"4","author":"Gomez","year":"2012","journal-title":"Front. Biosci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Madden, S., Carrazana, E., and Rabinowicz, A.L. (2023). Optimizing Absorption for Intranasal Delivery of Drugs Targeting the Central Nervous System Using Alkylsaccharide Permeation Enhancers. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082119"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Crowe, T.P., and Hsu, W.H. (2022). Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030629"},{"key":"ref_4","first-page":"1","article-title":"Imaging of intranasal drug delivery to the brain","volume":"10","author":"Veronesi","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0250-474X.41446","article-title":"Strategies for enhanced drug delivery to the central nervous system","volume":"70","author":"Dwibhashyam","year":"2008","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_6","first-page":"439","article-title":"Non-Invasive Strategies for Nose-to-Brain Drug Delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J. Clin. Trials"},{"key":"ref_7","first-page":"2088","article-title":"Nose to brain transport pathways an overview: Potential of nanostructured lipid carriers in nose to brain targeting","volume":"46","author":"Kousalya","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Bors","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","article-title":"Intranasal treatment of central nervous system dysfunction in humans","volume":"30","author":"Chapman","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100581","DOI":"10.1016\/j.ebr.2022.100581","article-title":"The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters","volume":"21","author":"Chung","year":"2022","journal-title":"Epilepsy Behav. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shrewsbury, S.B. (2023). The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and \u201cNose-to-Brain\u201d. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061720"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Xu, J., Tao, J., and Wang, J. (2020). Design and Application in Delivery System of Intranasal Antidepressants. Front. Bioeng. Biotechnol., 8.","DOI":"10.3389\/fbioe.2020.626882"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Aderibigbe, B.A. (2018). In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10020040"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Belenichev, I.F., Aliyeva, O.G., Popazova, O.O., and Bukhtiyarova, N.V. (2023). Involvement of heat shock proteins HSP70 in the mechanisms of endogenous neuroprotection: The prospect of using HSP70 modulators. Front. Cell. Neurosci., 17.","DOI":"10.3389\/fncel.2023.1131683"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/brainsci3010191","article-title":"Neuroprotective therapies after perinatal hypoxic-ischemic brain injury","volume":"3","author":"Cerio","year":"2013","journal-title":"Brain Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Andelius, T.C.K., B\u00f8gh, N., Pedersen, M.V., Omann, C., Andersen, M., Andersen, H.B., Hjortdal, V.E., Pedersen, M., Rasmussen, M.B., and Kyng, K.J. (2023). Early changes in cerebral metabolism after perinatal hypoxia-ischemia: A study in normothermic and hypothermic piglets. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1167396"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Min, Y.J., Ling, E.A., and Li, F. (2020). Immunomodulatory Mechanism and Potential Therapies for Perinatal Hypoxic-Ischemic Brain Damage. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.580428"},{"key":"ref_18","first-page":"133","article-title":"Nitrosative stress restriction in vitro conditions using modulators of thiol-disul-fide system","volume":"4","author":"Gorbacheva","year":"2015","journal-title":"Bull. Prob. Boil. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.13005\/bpj\/2850","article-title":"Comparative Assessment of the Effectiveness of HSP70\/HIF-1\u03b1 System Modulators after Prenatal Hypoxia","volume":"17","author":"Aliyeva","year":"2024","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_20","first-page":"86","article-title":"New original metabolitotropic endothelioprotector \u201cAngiolin\u201d: Quantum-chemical parameters and peculiarities of pharmacological action","volume":"8","author":"Chekman","year":"2017","journal-title":"Rep. NAS Ukraine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Belenichev, I., Popazova, O., Bukhtiyarova, N., Savchenko, D., Oksenych, V., and Kamyshnyi, O. (2024). Modulating Nitric Oxide: Implications for Cytotoxicity and Cytoprotection. Antioxidants, 13.","DOI":"10.3390\/antiox13050504"},{"key":"ref_22","first-page":"2584","article-title":"Report on Preclinical Study of Specific Biological Activity (Anti-Ischemic, Endothelioprotective) of the Drug Lisinium (Angiolin) at Parenteral Administration, Zaporozhye, Ukraine","volume":"11","author":"Kolesnik","year":"2018","journal-title":"Unpublished internal report"},{"key":"ref_23","first-page":"28","article-title":"Regarding L-lysine 3-methyl-1.2.4-triazole-5-thioacetate Standardization","volume":"1","author":"Kucherenko","year":"2017","journal-title":"Pharm. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00431-018-3279-7","article-title":"Intranasal breast milk for premature infants with severe intraventricular hemorrhage-an observation","volume":"178","author":"Keller","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature12880","article-title":"Intranasal epidermal growth factor treatment rescues neonatal brain injury","volume":"506","author":"Scafidi","year":"2014","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/nmeth.3663","article-title":"ANOVA and the analysis of drug combination experiments","volume":"12","author":"Ashton","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e01006","DOI":"10.1590\/s2175-97902018000001006","article-title":"Design of Experiments (DoE) applied to Pharmaceutical and Analytical Quality by Design (QbD)","volume":"54","author":"Fukuda","year":"2018","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41372-020-0654-9","article-title":"\u201cQuality of life\u201d: Parent and neonatologist perspectives","volume":"40","author":"Adams","year":"2020","journal-title":"J. Perinatol."},{"key":"ref_29","first-page":"199","article-title":"Impact of perinatal hypoxia on the developing brain","volume":"69","author":"Mach","year":"2020","journal-title":"Physiol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Millar, L.J., Shi, L., Hoerder-Suabedissen, A., and Moln\u00e1r, Z. (2017). Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges. Front. Cell. Neurosci., 11.","DOI":"10.3389\/fncel.2017.00078"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, B., Zeng, H., Liu, J., and Sun, M. (2021). Effects of Prenatal Hypoxia on Nervous System Development and Related Diseases. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.755554"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mielecki, D., Godlewski, J., and Salinska, E. (2024). Hyperbaric oxygen therapy for the treatment of hypoxic\/ischemic injury upon perinatal asphyxia\u2014Are we there yet?. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1386695"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ranjan, A.K., and Gulati, A. (2023). Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206653"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: Opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","article-title":"Intranasal delivery of cells to the brain","volume":"88","author":"Danielyan","year":"2009","journal-title":"Eur. J. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14739\/2409-2932.2023.1.267437","article-title":"Development of a spectrophotometric technique for the quantitative determination of ademol","volume":"16","author":"Semenenko","year":"2023","journal-title":"Curr. Issues Pharm. Med. Sci. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Dagda, R.K., Dagda, R.Y., Vazquez-Mayorga, E., Martinez, B., and Gallahue, A. (2023). Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010690"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3897\/pharmacia.68.e71243","article-title":"The effect of intranasal administration of an IL-1b antagonist (RAIL) on the state of the nitroxydergic system of the brain during modeling of acute cerebrovascular accident","volume":"68","author":"Burlaka","year":"2021","journal-title":"Pharmacia"},{"key":"ref_41","unstructured":"(1986). Council Directive 86\/609\/EEC of 24 November 1986 on the Approximation of Laws, Regulations and Administrative Provisions of the Member States Regarding the Protection of Animals Used for Experimental and Other Scientific Purposes. Off. J. Eur. Union, 358, 1\u201328."},{"key":"ref_42","first-page":"33","article-title":"Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the Protection of Animals Used for Scientific Purposes","volume":"276","author":"Buzek","year":"2010","journal-title":"Off. J. Eur. Union"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/990\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:24:10Z","timestamp":1760109850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ph17080990"],"URL":"https:\/\/doi.org\/10.3390\/ph17080990","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}